OtherBasic Science (Animal or Phantoms)
Preclinical evaluation of 203/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer
Sangeeta Ray Banerjee, IL Minn, Vivek Kumar, Anders Josefsson, Ala Lisok, Mary Brummet, Jian Chen, Ana Kiess, Kwamena Baidoo, Cory Brayton, Ronnie C Mease, Martin Brechbiel, George Sgouros, Robert F Hobbs and Martin G. Pomper
Journal of Nuclear Medicine June 2019, jnumed.119.229393; DOI: https://doi.org/10.2967/jnumed.119.229393
Sangeeta Ray Banerjee
1 Jonhs Hopkins University School of Medicine, United States;
IL Minn
2 Johns Hopkins University, United States;
Vivek Kumar
2 Johns Hopkins University, United States;
Anders Josefsson
3 Johns Hopkins University School of Medicine, United States;
Ala Lisok
2 Johns Hopkins University, United States;
Mary Brummet
2 Johns Hopkins University, United States;
Jian Chen
4 John Hopkins University, United States;
Ana Kiess
5 Johns Hopkins Medical Institute, United States;
Kwamena Baidoo
6 National Institutes of Health, United States;
Cory Brayton
5 Johns Hopkins Medical Institute, United States;
Ronnie C Mease
2 Johns Hopkins University, United States;
Martin Brechbiel
7 NCI, United States;
George Sgouros
3 Johns Hopkins University School of Medicine, United States;
Robert F Hobbs
2 Johns Hopkins University, United States;
Martin G. Pomper
8 Johns Hopkins Medical Institutions, United States

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 66, Issue 4
April 1, 2025
Preclinical evaluation of 203/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer
Sangeeta Ray Banerjee, IL Minn, Vivek Kumar, Anders Josefsson, Ala Lisok, Mary Brummet, Jian Chen, Ana Kiess, Kwamena Baidoo, Cory Brayton, Ronnie C Mease, Martin Brechbiel, George Sgouros, Robert F Hobbs, Martin G. Pomper
Journal of Nuclear Medicine Jun 2019, jnumed.119.229393; DOI: 10.2967/jnumed.119.229393
Preclinical evaluation of 203/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer
Sangeeta Ray Banerjee, IL Minn, Vivek Kumar, Anders Josefsson, Ala Lisok, Mary Brummet, Jian Chen, Ana Kiess, Kwamena Baidoo, Cory Brayton, Ronnie C Mease, Martin Brechbiel, George Sgouros, Robert F Hobbs, Martin G. Pomper
Journal of Nuclear Medicine Jun 2019, jnumed.119.229393; DOI: 10.2967/jnumed.119.229393
Jump to section
Related Articles
Cited By...
- Dosimetry in Radiopharmaceutical Therapy
- An Improved 211At-Labeled Agent for PSMA-Targeted {alpha}-Therapy
- Harnessing {alpha}-Emitting Radionuclides for Therapy: Radiolabeling Method Review
- Preclinical Evaluation of 213Bi- and 225Ac-Labeled Low-Molecular-Weight Compounds for Radiopharmaceutical Therapy of Prostate Cancer
- Preclinical Applications of Multi-Platform Imaging in Animal Models of Cancer